CANF: Can‐Fite submits Phase 2 protocol to test piclidenoson in Lowe syndrome (5‐patient open‐label)

AI Summary

Can‐Fite submitted a Phase 2 study protocol to Bambino Gesù Children’s Hospital and signed a collaboration with Fondazione Telethon to launch the first clinical evaluation of piclidenoson in Lowe syndrome, backed by preclinical data showing restoration of OCRL‐dependent cellular function. The open‐label, single‐center pilot will treat 5 genetically confirmed adult patients with oral piclidenoson twice daily for six months; the primary endpoint is improved renal 99mTc‐DMSA uptake (proximal tubular reabsorption) with urinary biomarkers and Fanconi syndrome parameters as secondary endpoints, and positive results are intended to inform regulatory discussions toward potential registration.

Positives

First clinical program for piclidenoson in Lowe syndrome with Phase 2 protocol submitted and collaboration with Fondazione Telethon
Preclinical data reportedly demonstrated restoration of OCRL‑dependent cellular function, providing a biological rationale
Study is explicitly designed as a regulatory‑enabling pilot to support discussions toward potential registration if positive

Negatives

Very small sample size (5 patients) limits statistical power and generalizability
Open‑label, single‑center design with no control arm reduces ability to distinguish drug effect from bias
Primary endpoint is an imaging surrogate (99mTc‑DMSA uptake) rather than direct long‑term clinical outcomes